论文部分内容阅读
探讨联合检测血清结合前列腺特异抗原(cPSA)、胰岛素样生长因子-1(IGF-1)、转化生长因子α(TGFα)对前列腺癌(PCa)的诊断价值。采用磁微粒免疫化学发光法(ICLMA)、IRMA和RIA,对46例PCa组、64例良性前列腺增生(BPH)组和73名健康男性对照组血清cPSAI、GF-1和TGFα进行测定,并动态观察37例PCa患者术后第1个月、3个月和6个月cPSAI、GF-1、TGFα含量。结果表明:PCa组血清cPSAI、GF-1和TGFα含量明显高于BPH组和对照组,有显著性差异(P<0.05)。IGF-1在PCa发展中有增高的趋势,但PCa临床各期之间无显著性差异(P>0.05)。cPSA、TGFα在PCa各期之间有显著性差异(P<0.05)。因此联合检测cPSAI、GF-1和TGFα对PCa的预测、诊断及疗效监测有一定意义,同时cPSA和TGFα可为PCa临床分期提供依据。
To investigate the diagnostic value of combined detection of serum PSA, IGF-1 and TGFα in prostate cancer (PCa). The serum levels of cPSAI, GF-1 and TGFα in 46 patients with PCa, 64 with benign prostatic hyperplasia (BPH) and 73 healthy controls were measured by magnetic particle immunochemiluminescence (ICLMA), IRMA and RIA, 37 cases of PCa patients after 1 month, 3 months and 6 months cPSAI, GF-1, TGFα content. The results showed that the levels of cPSAI, GF-1 and TGFα in PCa group were significantly higher than those in BPH group and control group (P <0.05). IGF-1 has an increasing trend in the development of PCa, but no significant difference between PCa clinical stages (P> 0.05). There was a significant difference of cPSA and TGFα between PCa stages (P <0.05). Therefore, the combined detection of cPSAI, GF-1 and TGFαhas a certain significance in the prediction, diagnosis and curative effect monitoring of PCa. Meanwhile, cPSA and TGFαcan provide the basis for clinical staging of PCa.